Trials / Completed
CompletedNCT02538016
TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study
Use of Tolvaptan, a Vasopressin Antagonist, to Increase Urine Dilution and Reduce Cystine Urolithiasis Among Patients With Homozygous Cystinuria: a Pilot Investigation
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Caleb Nelson · Academic / Other
- Sex
- All
- Age
- 12 Years – 29 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this research project is to establish that in short-term use, tolvaptan is a safe and potentially effective new therapy for cystinuria, by conducting a short-term pilot study of the safety and tolerability of this drug, and assess impact on urinary stone risk parameters, among adolescent and young adult patients with clinical cystinuria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tolvaptan |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2015-09-02
- Last updated
- 2020-07-10
- Results posted
- 2020-06-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02538016. Inclusion in this directory is not an endorsement.